Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Etopophos

(etoposide phosphate)

Phase 3Small molecule

GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH

Etoposide phosphate is used to treat certain types of cancer, including lung cancer and testicular cancer, by stopping cancer cells from dividing and growing.[1] Etopophos is currently being investigated across 21 indications[3], with its most advanced program in Phase 3.[1]

Etopophos is one of 415 small molecule programs targeting Primitive Neuroectodermal Tumor. It is currently in Phase 3.

21

Indications

55

Total Trials

14

Active Trials

414

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primitive Neuroectodermal TumorActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Anaplastic Large Cell LymphomaActive, not recruiting

LymphomaActive, not recruiting

Germ Cell TumorActive, not recruiting

Hodgkins LymphomaActive, not recruiting

NeuroblastomaActive, not recruiting

Hemophagocytic SyndromeActive, not recruiting

Ewing SarcomaActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Primitive Neuroectodermal TumorPreclinical

Active, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Anaplastic Large Cell LymphomaPreclinical

Active, not recruiting

LymphomaPhase 3

Active, not recruiting

Germ Cell TumorPhase 3

Active, not recruiting

Hodgkins LymphomaPreclinical

Active, not recruiting

NeuroblastomaPhase 3

Active, not recruiting

Hemophagocytic SyndromePhase 2

Active, not recruiting

Ewing SarcomaPhase 3

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Showing 10 of 21 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Etopophos

GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH

Zofran

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Nuvigil

NNuvo Research GmbH

Systemic Therapy

Bristol-Myers Squibb

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

VP-16

FFundamenta Therapeutics, Ltd.

Stem Cells

KKang Stem Biotech Co., Ltd.

R-CHOP

IIncyte Biosciences Japan GK

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Metastatic Ewing Sarcoma

NCT02306161

Q4 2026

Phase 3Active, not recruiting

Mediastinal Large B-Cell Lymphoma

NCT04759586

Q2 2029

Phase 3Recruiting

Safety and Efficacy

NCT06188676

Q2 2030

Phase 2Recruiting

Medulloblastoma

NCT01356290

Phase 2Active, not recruiting

Rhabdomyosarcoma

NCT01871766

Clinical

Trials by Indication[1]

Lymphoma12 trials

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT00302003·287 enrolled

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT02130869·8 enrolled

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Recruiting·UUniversity of Birmingham·Phase 2/3·NCT05991388·210 enrolled

Show 9 more trials

Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma

Completed·WWashington University School of Medicine·Phase 2·NCT01969435·50 enrolled

Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00002880·53 enrolled

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Completed·UUniversity of California, San Francisco·N/A·NCT00416819·10 enrolled

Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00974792·150 enrolled

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Active, not recruiting·—·Phase 2·NCT03113500·48 enrolled

Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00074178·22 enrolled

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01132807·164 enrolled

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT01026220·166 enrolled

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02106988·40 enrolled

Neuroblastoma6 trials

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Recruiting·CChildren's Oncology Group·Phase 3·NCT03126916·750 enrolled

Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

Unknown status·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·Phase 3·NCT00410631·642 enrolled

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Completed·CChildren's Oncology Group·Phase 1·NCT01175356·99 enrolled

Show 3 more trials

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma

Completed·CChildren's Oncology Group·Phase 2·NCT00017368·42 enrolled

Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

Unknown status·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·N/A·NCT00526318·360 enrolled

Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00417053

Acute Lymphoblastic Leukemia3 trials

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01256398·66 enrolled

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00873093·148 enrolled

Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Unknown status·OOhio State University Comprehensive Cancer Center·Phase 2·NCT01005758·180 enrolled

Small Cell Lung Cancer3 trials

Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer

Completed·UUniversity College, London·Phase 3·NCT00433498·846 enrolled

Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Withdrawn·CCancer Trials Ireland·Phase 1·NCT01160731

Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer

Unknown status·EEBMT Solid Tumors Working Party·Phase 3·NCT00011921·430 enrolled

Germ Cell Tumor3 trials

Combination Chemotherapy and Radiation Therapy in Treating Patients With Germ Cell Tumors in the Brain

Completed·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00293358·500 enrolled

Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors

Completed·MMedical Research Council·Phase 2·NCT00301782·88 enrolled

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT02375204·420 enrolled

23 more indications

Chemotherapy2 trials

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Recruiting·CC17 Council·Phase 1·NCT06942039·15 enrolled

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT04116359

Malignant Brain Tumors2 trials

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT00238173·2 enrolled

Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors

Unknown status·OOHSU Knight Cancer Institute·Phase 2·NCT00075387·48 enrolled

Acute Myeloid Leukemia2 trials

Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01249430·24 enrolled

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03983824·48 enrolled

Carboplatin2 trials

Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

Unknown status·GGOG Foundation·Phase 2·NCT01042522·63 enrolled

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00074165·17 enrolled

Diffuse Large B-Cell Lymphoma2 trials

Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma

Unknown status·UUniversity Hospital Southampton NHS Foundation Trust·N/A·NCT00689845·120 enrolled

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Completed·—·Phase 1·NCT03440567·16 enrolled

Relapsed or Refractory Hematologic Malignancies1 trial

Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT01900509·16 enrolled

Safety and Efficacy1 trial

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Recruiting·NNational Research Center for Hematology, Russia·Phase 3·NCT06188676·100 enrolled

Multiple Myeloma1 trial

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00005792·131 enrolled

Primitive Neuroectodermal Tumor1 trial

Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma

Completed·UUniversitätsklinikum Hamburg-Eppendorf·N/A·NCT00303810·567 enrolled

Anaplastic Large Cell Lymphoma1 trial

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Unknown status·EEuropean Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma·N/A·NCT00317408·96 enrolled

Nasopharyngeal Carcinoma1 trial

Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma

Terminated·UUniversity of Florida·Phase 3·NCT02137096·1 enrolled

Medulloblastoma1 trial

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Recruiting·MMedical University of Vienna·Phase 2·NCT01356290·232 enrolled

Central Nervous System1 trial

Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00867178·33 enrolled

Side Effects1 trial

Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer

Unknown status·CChildren's Cancer and Leukaemia Group··NCT00897871·60 enrolled

Children1 trial

Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL

Completed·UUniversitätsklinikum Hamburg-Eppendorf·Phase 2/3·NCT01228331·745 enrolled

Malignant Solid Tumors1 trial

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Terminated·—·Phase 1/2·NCT00788125·7 enrolled

Ovarian Cancer1 trial

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 1/2·NCT00003064·30 enrolled

Brain Tumors1 trial

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors

Completed·OOHSU Knight Cancer Institute·Phase 1/2·NCT00303849·33 enrolled

Rhabdomyosarcoma1 trial

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01871766·115 enrolled

Hodgkin Lymphoma1 trial

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT05675410·1,875 enrolled

Mediastinal Large B-cell Lymphoma1 trial

A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT04759586·244 enrolled

Metastatic Ewing Sarcoma1 trial

Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02306161·312 enrolled

Recurrent Diffuse Large B-Cell Lymphoma1 trial

A Phase 2 Study of Epcoritamab (Epco) Plus Physician's Choice of Platinum-Containing Chemotherapy Pre-Autologous Hematopoietic Cell Transplantation (AutoHCT) Followed by Post-AutoHCT Epco Consolidation/ Maintenance in Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL)

Recruiting·JJoseph Tuscano·Phase 2·NCT06905509·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 55 trial records for etoposide phosphate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — etoposide phosphate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for etoposide phosphate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — German Society for Pediatric Oncology and Hematology GPOH gGmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Topoisomerase II Alpha Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH

Related News